March 27, 2025
TOPLINE: Hidradenitis suppurativa (HS) treatment choices were shaped by past experiences, healthcare provider recommendations, and patient beliefs in the United Kingdom; a new study emphasised the […]
March 25, 2025
TOPLINE: Nemolizumab was well tolerated and provided lasting relief from itching and disease severity while improving quality of life in patients with prurigo nodularis (PN) over […]
March 24, 2025
A recent analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) data found that beyond the reported associated risks for depression and suicidality, […]
March 21, 2025
ORLANDO, Fla. — A study of automated three-dimensional total-body photography (3D TBP) found that it improved “hit” rates of positive malignant biopsies and reduced unnecessary biopsies […]
March 20, 2025
ORLANDO, Fla. — Dosing of the oral Janus kinase (JAK) inhibitor upadacitinib can be increased or decreased in adult patients with moderate to severe atopic dermatitis […]
March 20, 2025
ORLANDO, Fla. — Of the 12 biologics in four drug classes approved for treating psoriasis in the United States, interleukin 23 (IL-23) inhibitors might be exceptional, […]
March 20, 2025
TOPLINE: Upadacitinib was well tolerated in patients with moderate to severe atopic dermatitis (AD) and led to disease control as early as 1 month, with sustained […]
March 20, 2025
TOPLINE: Poor outcomes in patients with cutaneous squamous cell carcinoma (CSCC) were more likely if they had additional risk factors, a multinational study found. METHODOLOGY: A […]
March 18, 2025
ORLANDO, Fla. — Adolescents with severe or very severe alopecia areata (AA) were able to regrow hair, some with a 90% improvement in hair loss, after […]